Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, interleaved, ascending dose study, to evaluate safety, tolerability and pharmacokinetics of single oral doses of AQW051; to evaluate the effect of food on the pharmacokinetics of AQW051, in Japanese healthy male subjects

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, interleaved, ascending dose study, to evaluate safety, tolerability and pharmacokinetics of single oral doses of AQW051; to evaluate the effect of food on the pharmacokinetics of AQW051, in Japanese healthy male subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VQW 765 (Primary)
  • Indications Psychotic disorders
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
  • 21 Jun 2007 Status change from in progress to completed
  • 30 Dec 2006 Status change

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top